External Source

Dr Subbiah On Outcomes With Larotrectinib In Trk Fusion–positive Solid Tumors

2024 1:06
Synopsis
Vivek Subbiah, MD, chief, Early-Phase Drug Development, Sarah Cannon Research Institute, discusses key data from the ...

You Might Also Like

Updated Data With Larotrectinib in TRK Fusion-Positive Solid Tumors 1:20
Updated Data With Larotrectinib In Trk Fusion-positive Solid...
2019
Larotrectinib, a TRK inhibitor for patients with solid tumors 1:15
Larotrectinib, A Trk Inhibitor For Patients With Solid Tumor...
2021
Vivek Subbiah, MD, describes solid tumor tests for RET fusion and similarities to other therapies 1:37
Vivek Subbiah, Md, Describes Solid Tumor Tests For Ret Fusio...
2020
The impact of TRK inhibitor LOXO-101 (larotrectinib) on patients with TRK fusion cancers 0:52
The Impact Of Trk Inhibitor Loxo-101 (larotrectinib) On Pati...
2017
Dr. Subbiah on Safety and Efficacy of BLU-667 in RET-Altered Solid Tumors 1:14
Dr. Subbiah On Safety And Efficacy Of Blu-667 In Ret-altered...
2018
Larotrectinib Is Well-Tolerated in Metastatic Solid Tumors 0:39
Larotrectinib Is Well-tolerated In Metastatic Solid Tumors
2020
Dr. Drilon on Activity of Larotrectinib in TRK Fusion–Positive NSCLC 1:35
Dr. Drilon On Activity Of Larotrectinib In Trk Fusion–posi...
2019
ARROW: clinical activity of pralsetinib in RET-fusion positive solid tumors 6:04
Arrow: Clinical Activity Of Pralsetinib In Ret-fusion Positi...
2021
Larotrectinib for Solid Tumors With NTRK Gene Fusions 7:14
Larotrectinib For Solid Tumors With Ntrk Gene Fusions
2019
Dr. Subbiah on the FDA Approval of Pralsetinib in RET+ NSCLC 1:07
Dr. Subbiah On The Fda Approval Of Pralsetinib In Ret+ Nsclc
2020
How Will Larotrectinib Be Used? 2:10
How Will Larotrectinib Be Used?
2018
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.